Trusted By
The problem
Why Traditional Radiology Data Fails Research?
Medical research is hindered by limited access to diverse, high-quality imaging data:
Lack of Diversity
Bias in patient demographics & disease representation.
Slow Data Acquisition
Real-world imaging data takes months or years to gather.
Inconsistent Imaging Protocols
Variability across scanners affects AI accuracy.
High Costs
Recruiting and scanning real patients is expensive.
Our solution
AI-Powered Radiology Data, Redefined
Sinkove’s AI-powered digital twin technology transforms medical imaging research by generating synthetic patient datasets tailored to your specific needs. Our solution eliminates data scarcity, bias, and inconsistencies, making AI model training and clinical research faster, more reliable, and cost-effective.
How It Works
1. Customise
Tailor our pre-trained AI to your proprietary datasets and requirements.
2. Generate
Create digital twins for diverse, realistic imaging across disease subtypes.
3. Measure
Validate synthetic data for accuracy, reliability, and regulatory compliance.
4. Integrate
Seamlessly use AI-generated datasets in your existing research workflows.
Impact
Addressing Key Challenges in Clinical Research
Eliminating Data Bias & Improving Diversity
Sinkove enables the generation of balanced, diverse imaging datasets with various patient demographics, disease subtypes, and imaging protocols.
Result: AI models perform more accurately across all population groups.
Accelerating Research Timelines
AI-driven imaging eliminates the need for months or years of real-world data collection.
Result: Researchers generate high-quality imaging datasets in seconds.
Standardising Imaging Data Across Protocols
Our AI converts imaging data from different scanners into a unified, standardized format.
Result: Clinicians and researchers gain consistent, comparable datasets, eliminating variability issues.
Reducing High Costs of Patient Recruitment
AI-driven virtual patients replace the need for costly real-world recruitment.
Result: Simulating control groups in drug trials reduces the number of real patients needed, lowering trial costs while ensuring statistically powerful results.